Patent: 8,552,052
✉ Email this page to a colleague
Summary for Patent: 8,552,052
Title: | Use of diindolylmethane-related indoles for the treatment and prevention of respiratory syncytial virus associated conditions |
Abstract: | The present invention includes compositions and methods for the treatment and prevention of conditions associated with Respiratory Syncytial Virus (RSV) infection. RSV-associated conditions include acute infections in mammals, typically bronchiolitis and pneumonia, and post-infectious chronic respiratory conditions. In particular, the present invention describes new therapeutic and preventative uses for 3,3\'-diindolylmethane (DIM), or a DIM-related indole, alone or in combination with an inhibitor of a membrane bound Epidermal Growth Factor Receptor (EGFR) inhibitors, to treat conditions associated with exposure to RSV. |
Inventor(s): | Zeligs; Michael A. (Boulder, CO) |
Assignee: | BioResponse, L.L.C. (Boulder, CO) |
Application Number: | 13/164,488 |
Patent Claims: | see list of patent claims |
Details for Patent 8,552,052
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Hoffmann-la Roche Inc. | PEGASYS COPEGUS COMBINATION PACK | peginterferon alfa-2a and ribavirin | 125083 | 06/04/2004 | ⤷ Try a Trial | 2024-12-30 | |
Schering Corporation A Subsidiary Of Merck & Co., Inc. | PEGINTRON/ REBETOL COMBO PACK | peginterferon alfa-2b and ribavirin | 125196 | 06/13/2008 | ⤷ Try a Trial | 2024-12-30 | |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |